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Abstract: Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and do-
paminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and nore-
pinephrine neurotransmission. Current drug development efforts are aimed at a new class of antidepressants which inhibit 
the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset 
of action. The current review explores limitations of presently available antidepressants and the history and premise be-
hind the movement to devise triple reuptake inhibitors. The evidence for and against the claim that broader spectrum 
agents are more efficacious is discussed. Examples of triple reuptake inhibitors in development are compared, and pre-
clinical and clinical research with these agents to date is described.  
INTRODUCTION  
  Since the catecholamine hypothesis of depression was 
first described in the 1960’s, most antidepressant drug devel-
opment has targeted the enhancement of monoamine neuro-
transmission. For decades tricyclic antidepressants (TCAs), 
which inhibit the reuptake of norepinephrine and serotonin, 
were the principal treatment choice for clinicians; unfortu-
nately these agents have classic side effects as a result of 
histaminergic, cholinergic, and alpha-adrenergic receptor 
antagonism. Additionally, TCAs have a low therapeutic in-
dex related to quinidine-like cardiac conduction effects 
which make them quite dangerous in overdose. Monoamine 
oxidase inhibitors have also been in use for approximately 
fifty years, but their inhibition of monoamine catabolism 
predisposes them to drug-drug interactions as well as interac-
tions with dietary tyramine. In the past two decades, antide-
pressant drug development efforts have focused on improv-
ing tolerability which has led to molecules that specifically 
inhibit serotonin reuptake (SSRI) or both serotonin and 
norepinephrine reuptake (SNRI). These agents have more 
benign side effect profiles than TCAs or monoamine oxidase 
inhibitors (MAOIs), although they have not shown advan-
tages in efficacy or in onset of antidepressant response 
[41,48]. To date, only 65% of patients treated with antide-
pressants experience therapeutic response [41,48,36,39], 
even after multiple steps of antidepressant treatment, aug-
mentation, and switching as noted in the recent Sequenced 
Treatment Alternatives to Relieve Depression (STAR-D) 
trial [38]. Additionally, typical onset of action of antidepres-
sants does not occur until approximately 2-4 weeks [33,47]. 
Current development efforts include the evaluation of triple 
reuptake inhibitors which block the reuptake of serotonin, 
norepinephrine, and dopamine from the synapse. It is theo-
rized that the additive effect of enhancing neurotransmission 
in all three monoamine systems (“broad spectrum”) may lead 
to improved efficacy and quicker onset of antidepressant 
response.  
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THE TRIPLE-ACTION HYPOTHESIS  
  Copious evidence links depression to deficiencies in neu-
rotransmission of the monoamines serotonin, norepinephrine, 
and dopamine [7,34,35,43,54]. As described, TCAs and 
MAOIs became used widely for depression after they were 
serendipitously discovered to be efficacious in depressed 
patients. Subsequent study demonstrated that these medica-
tions work by inhibiting the norepinephrine and serotonin 
transporters (e.g. TCAs) [2] and by inhibiting the intracellu-
larcatabolism of norepinephrine and serotonin (e.g. MAOIs). 
Simultaneously, depletion studies revealed that depression 
was a consequence of deficient norepinephrine and serotonin 
[8,9,55]. Rational drug design later led to SSRIs and SNRIs 
which have successfully led to reduced side effect burden as 
a result of their selectivity for monoamine reuptake sites. 
Other antidepressants have been developed which enhance 
norepinephrine and serotonin neurotransmission via other 
mechanisms; such medications include mirtazepine (presyn-
aptic alpha-2 adrenergic antagonist), as well as trazodone 
and nefazodone (primarily presynaptic and postsynaptic 5-
HT2 antagonists). Less attention has been given to affecting 
dopamine transmission in depression, although data indicate 
the important role of mesolimbic dopamine in moderating 
motivation and reward-related behavior which are typically 
disrupted in depression [29,44]. Furthermore, antidepressants 
have been shown to sensitize mesolimbic dopamine recep-
tors in animal and human studies, findings which have led to 
the hypothesis that enhancing synaptic dopamine availability 
may lead to more rapid antidepressant response [44]. The 
dopamine and norepinephrine reuptake inhibitor bupropion 
was developed in the 1980’s as an antidepressant [53], and it 
has since been repeatedly shown to boost the therapeutic 
response to norepinephrinergic and/or serotonergic antide-
pressants (and decrease sexual side effects) when used as 
augmentation [5,12,56]. Additional data indicate that the 
stimulant class of medications, which induce release and 
block reuptake of dopamine and norepinephrine, augment 
and hasten antidepressant response when combined with 
TCAs [10,18,52], MAOIs [13,14], and SSRIs/SRNIs [27, 
49]. Finally, dopamine agonists themselves (bromocriptine, 
pergolide) have shown efficacy as augmenting agents with 
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Thus, it seems that serotonin, norepinephrine, and dopamine 
systems are all related to the pathophysiology of depression 
and as such are relevant targets for pharmacological inter-
vention. This premise has ushered the development of medi-
cations which enhance neurotransmission of all three sys-
tems in an effort to provide more reliable efficacy and 
quicker therapeutic effect.  
IS BROADER BETTER? 
  Prior to the 1980’s, drug candidates were identified by 
testing laboratory-derived compounds in animal models and 
observing the effects. As biochemical and genetic research 
identified the molecular mechanisms that underlie disease, 
drug development began to focus on increasing selectivity 
with the goal of affecting only the target molecule identified 
as relevant in order to minimize side effects [16]. However, 
clinical studies of complex disorders as diverse as cancer and 
schizophrenia reveal that “dirty” drugs affecting a variety of 
targets tend to have better efficacy [16].  
  In a reversal of the move towards selectivity that led to 
the SSRIs in the 1980’s and 1990’s, the SNRIs were devel-
oped under the premise that a broader spectrum of neuro-
transmitter reuptake inhibition would lead to greater antide-
pressant efficacy and/or more rapid onset of action. Data 
accumulated to date is mixed regarding the usefulness of this 
strategy. With regard to rapidity of onset, venlafaxine per-
formed well in a placebo-controlled trial in hospitalized de-
pressed patients, demonstrating efficacy benefit within one 
week of treatment initiation [17]. Similarly, venlafaxine pro-
duced earlier time to remission of depression compared to 
SSRIs in an open-label trial [40]. A meta-analysis of eight 
studies comparing venlafaxine to SSRIs and placebo demon-
strates earlier time to remission in venlafaxine-treated pa-
tients consistently across age and gender groups [11]. The 
authors also cite remission rates of 45%, 35%, and 25% in 
patients treated with venlafaxine, SSRIs, and placebo respec-
tively, yielding an odds ratio for remission of 1.5 favoring 
venlafaxine over SSRIs [50]. Two more recent large meta-
analyses of studies comparing SNRIs to SSRIs revealed a 
smaller efficacy advantage in favor of SNRIs (4.3-5.9% 
higher remission rate) [30,32]. In these later meta-analyses, 
the number needed to treat (NNT) statistic shows that 17-24 
patients would need to be treated with SNRIs to yield one 
additional responder [30,32], confronting the notion that 
SNRIs offer a clinically relevant advantage over SSRIs with 
respect to likelihood of achieving remission of depression.  
  Other data endorse the thrust towards increased neuro-
transmitter selectivity. In particular, a meta-analysis of the 
highly selective SSRI escitalopram (S-isomer of citalopram) 
suggests that this medication is superior in efficacy to other 
SSRIs and to the SNRI venlafaxine (grouped together) on the 
outcomes of response rate, remission rate, and overall treat-
ment outcome [24]. A second meta-analysis indicates more 
rapid onset of action of escitalopram compared to other 
SSRIs and venlafaxine extended-release (grouped together) 
[22]. Thus, it remains controversial whether certain antide-
pressants confer clinically relevant advantages in rapidity of 
onset or overall efficacy for depression, and whether such 
differences are related to the breadth of their neurotransmit-
ter reuptake inhibition.  
  It should also be noted that currently available dual reup-
take inhibitors differ in their relative potencies at monoamine 
transporters. Milnacipran blocks serotonin and norepineph-
rine reuptake equally, whereas greater selectivity at serotonin 
reuptake sites is characteristic of venlafaxine (30-fold) and 
duloxetine (10-fold) [37]. Clinical ramifications of these in
vitro differences in selectivity are poorly understood.  
EXAMPLES OF COMPOUNDS IN DEVELOPMENT 
  Despite the structural similarity of the norepinephrine, 
serotonin, and dopamine transporters, synthesis of bioavail-
able and safe molecules which appreciably inhibit all three 
transporters has been challenging [46]. Additionally, the 
optimal selectivity at the three transporter sites is unknown, 
and it is plausible that different potency ratios mean different 
clinical effects. Two families of compounds in development 
are analogs of the dual reuptake inhibitors milnacipran and 
venlafaxine. In particular, racemic analogs of venlafaxine 
referred to as PRC025 and PRC050 are highly potent at hu-
man norepinephrine (NE), serotonin (SER), and dopamine 
(DA) transporters and inhibit the reuptake of these mono-
amines into rat brain synaptosomes [39]. These compounds 
exhibited antidepressant-like characteristics equal to imi-
pramine in well-accepted rat models of antidepressant effect; 
both PRC025 and PRC050 increased time spent swimming 
and reduced time spent immobile in the forced swim test and 
reduced time spent immobile in the tail suspension test [39]. 
Several milnacipran derivatives have been developed in 
search of molecules with more potent N-methyl-D-aspartic 
acid (NMDA) antagonism [23,42 cited in 37]. More recently, 
analogs have been synthesized to evaluate their relative 
monoamine transporter inhibition potency and selectivity. 
An isomer of one such analog (-)-8h functions as a triple 
reuptake inhibitor in vitro [37]. To date, animal or human 
antidepressant studies have not been published with this 
compound.  
  DOV Pharmaceutical, Inc. has developed triple reuptake 
inhibitors from a class of azabicyclohexanes chemically re-
latedtobicifadine.Three of these compounds (DOV 216,303, 
DOV 21,947, and DOV 102,677) have been shown to block 
transport of human recombinant NE, SER, and DA trans-
porters with clinically-relevant potency (Table 1) [4,34,44, 
45]. Also, all three of these compounds demonstrated antide-
pressant properties in rodent models; 21,947 reduced immo-
bility during forced swim test and tail suspension test [45], 
102,677 reduced immobility during forced swim test [34], 
and 216,303 reduced immobility during forced swim test and 
reversed tetrabenazine-induced ptosis [44]. Human studies 
with DOV 216,303 show that it is well-tolerated at clinically 
appropriate doses with minor gastrointestinal side effects 
ranging from 19-57% [4,44,]. A small citalopram-controlled 
clinical trial of DOV 216,303 (N=67) yielded significant 
improvements in Hamilton Depression Rating Scale (HAM-
D) scores in both groups at both the one-week and two-week 
time points, although the study lacked a placebo group [44]. 
Bicifadine (1-p-tolyl-3-azabicyclo[3.1.0]hexane) itself has 
been pharmacologically characterized, and it has been shown 
to inhibit monoamine neurotransmitter uptake by recombi-
nant human transporters in vitro with a relative potency of 
NE:SER:DA of 1:2:17 [3]. To date, published preclinical 340    Current Neuropharmacology, 2008, Vol. 6, No. 4 Marks et al. 
research has focused on the potential antinociceptive proper-
ties of bicifadine [3], although its utility as an antidepressant 
warrants exploration.  
  The novel triple reuptake inhibitor tesofensine (NS 2330) 
has not been systematically studied regarding its clinical or 
preclinical antidepressant effects. Similar to antidepressants 
[6], this agent has demonstrated neuroprotective effects in-
cluding increasing brain derived neurotrophic factor (BDNF) 
and neuronal proliferation in the rat hippocampus [26].  
  It is likely that other triple reuptake inhibitors are in vari-
ous developmental phases, and the current discussion of 
compounds in development should not be considered ex-
haustive. A summary of described compounds appears below 
in Table 1.   
OTHER POTENTIAL INDICATIONS FOR TRIPLE 
REUPTAKE INHIBITORS  
  Like other classes of antidepressant medications, triple 
reuptake inhibitors likely hold promise for a variety of thera-
peutic indications. One emerging area of research concerns 
the potential antinociceptive effects of triple inhibitors, 
which is expected given the copious data supporting the util-
ity of TCAs and SNRIs for pain syndromes. Preclinical re-
search with bicifadine demonstrates its antinociceptive ef-
fects in animal models of acute, persistent, and chronic pain 
including inflammatory, visceral, and nociceptive paradigms. 
Table 1.  Summary of Characteristics and Pharmacokinetic Parameters of Triple Reuptake Inhibitors in Development 
Products Compounds 
Other 
Characteristics 
Evidence of Anti-
depressant Poten-
tial 
Half- 
Life 
(hr) 
Tmax  
(Time to peak 
Concentration 
in hrs) 
Affinity 
Ki
(nm/L) 
NE:SER:DA 
Potency 
IC50
(n M) 
NE:SER:DA
PRC025 
[39] 
(2SR, 3RS)-N,N-dimethyl-3-
cyclohexyl-3-hydroxy-2-(2-
naphthyl)propylamine 
Racemic ana-
logue of  
venlafaxine  
Animal/Preclinical     10: 6: 53   
PRC050 
[39] 
(2RS,3RS)-N-methyl-3-
hydroxy-2-(2-naphthyl)-3-
phenylpropylamine  
Racemic ana-
logue of  
venlafaxine  
Animal/Preclinical     1.2: 12: 43   
DOV
216,303 
[4,44] 
[(±)-1-(3,4-dichlorophenyl)-
3-azabicyclo-[3.1.0]hexane 
hydrochloride].
Animal/Preclinical
Small human clini-
cal trial (not pla-
cebo-controlled) 
Approx. 
3.3 to  
4.4  
Approx. 1    21: 14: 78 
DOV 21,947
[45] 
[(+)-1-(3,4-dichlorophenyl)-
3-azabicyclo-[3.1.0]hexane 
hydrochloride]
(+)-enantiomer 
of  
DOV 216,303 
Animal/Preclinical     262: :99: 213  23: 12: 96 
DOV
102,677 
[34] 
[(–)-1-(3,4-dichlorophenyl)-
3-azabicyclo-[3.1.0]hexane 
hydrochloride]) 
(-)-enantiomer 
of  
DOV 216,303 
Animal/Preclinical 1030: 740: 
222
103: 133: 
129
(-)-8h 
[37] 
(-)-(1R, 2S)-naphthyl deriva-
tive of milnacipran 
  None        5: 18: 140 
Bicifadine 
[3] 
 (+/-)-1-(4-methylphenyl)-3-
azabicyclo-[3.1.0]hexane 
HCl)] 
DOV 220,075  None  Approx. 
3.5 
Approx. 
1
5.0: 2.4: 5.2  
(EM) 
55: 117: 910 
Tesofensine 
(NS2330) 
[26] 
8-azabicyclo[3.2.1]octane,3-
(3,4-dichlorophenyl)-2-
(ethoxymethyl)-8-methyl-, 
[1R-(2-endo,3-exo)]-,2-
hydroxy-1,2,3-
propanetricarboxylate 
 None  Approx. 
230
Approx. 
6-8 
  1.7: 11: 65 
IC50: concentration required for 50% inhibition in vitro.
Ki: binding affinity of the inhibitor. 
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These effects were reduced in some experimental conditions 
by the coadminstration of sulpride (a dopamine-2 receptor 
antagonist), suggesting that enhancement of dopamine neu-
rotransmission is important for the full antinociceptive effect 
of bicifadine [3].   
  The prodopaminergic potential of tesofensine led to a 
proof-of-concept study of this agent in the treatment of Park-
inson’s disease (PD). In this adequately-powered study 
(N=261) with multiple dosage arms corresponding to up to 
77% DA transporter occupancy, tesofensine did not outper-
form placebo [19]. Two smaller open-label studies of 
tesofensine and the related compound brasofensine also 
failed to demonstrate benefit in PD [15,51]. One possible 
explanation is homeostatic reduction in DA synthesis and 
release [19]. In contrast, in a phase IIa pilot study in Alz-
heimer’s disease, tesofensine treatment was associated with 
cognitive improvements [51 cited in 19]; the physiological 
mechanism of this observation is unclear, although it has 
been proposed that tesofensine indirectly stimulates cho-
linergic neurotransmission [51].  
  Weight loss has been observed as an adverse event in 
studies of tesofensine [19], prompting further research for 
the indication of obesity. The pharmaceutical company Neu-
rosearch has conducted a phase IIb proof-of-concept dose-
finding study and a subsequent study of metabolic outcomes 
using tesofensine; both of these studies indicate that teso-
fensine is efficacious in promoting weight loss in obese sub-
jects [1]. The triple reuptake inhibitor sibutramine is ap-
proved by the United States Food and Drug Administration 
(FDA) for the indication of obesity. Research is generally 
lacking regarding the antidepressant potential of sibutramine, 
although a small study in obese and overweight subjects 
(N=60) suggests that it has mood-enhancing effects [25].  
  One published preclinical study describes the effect of 
the “balanced” triple reuptake inhibitor DOV 102,677 in 
reducingvolitionalalcohol consumption in ethanol-preferring 
rats without decreasing food or water consumption [28]. It 
should be noted that monoamine reuptake inhibitors have 
historically performed better in animal models of addiction 
than in human clinical trials. However, it is possible that 
agents which inhibit dopamine reuptake may offer improved 
efficacy in addictive disorders due to the link between do-
pamine and reward-motivated behaviors. Subsequent clinical 
trials in subjects with addictive disorders will elucidate the 
potential for triple reuptake inhibitors to reduce addictive 
behaviors.   
CONCLUSIONS  
  The impetus to develop triple reuptake inhibitors is a 
natural consequence of the rich drug development history 
occurring over the past fifty years. We have come a long 
way since the serendipitous discovery that TCAs and MAOIs 
exert antidepressant effects. Rational drug design has al-
lowed us to customize the receptor profiles of potential anti-
depressant drugs and to target specific monoamine reuptake 
transporters. Current strategies involve developing multiple 
analogues of dual reuptake inhibitors and characterizing their 
receptor profiles in order to develop a quiver of molecules 
with clinically-relevant activity at all three monoamine reup-
take sites. The ideal ratio of transporter site potencies that a 
triple reuptake inhibitor should exhibit remains unknown, 
and hopefully the diversity of molecules in development will 
shed light on this issue. Future research will undoubtedly 
involve clinical study of various triple reuptake inhibitors to 
determine whether any of them offer advantages over cur-
rently approved antidepressants in efficacy, rapidity of onset, 
or side effect profile. Research published to date tends to 
support that antidepressants vary modestly in various out-
comes related to efficacy. Yet, findings are mixed regarding 
whether broader spectrum agents or highly serotonin-
selective agents confer the best efficacy. Furthermore, con-
cern has been expressed that triple reuptake inhibitors may 
produce broader side effect burden without enhancing effi-
cacy over more selective agents [31]. In actuality, it is plau-
sible that triple reuptake inhibitors that minimize blockade at 
histaminergic, cholinergic, and alpha-adrenergic receptors 
may yield the most favorable tolerability of all antidepres-
sants with less sexual side effects than SSRIs or SNRIs. By 
way of example, bupropion has long been used to treat anti-
depressant-related sexual dysfunction, presumably through 
its dopaminergic effects [19]. Many of these questions will 
be answered by subsequent research.   
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